Subcutaneous Orencia: Ph III ASTRAEA data

The double-blind, international Phase III ASTRAEA trial in 424 patients with psoriatic arthritis who had a ≥2 cm target lesion of plaque psoriasis

Read the full 238 word article

User Sign In